1-4 of 4
R. Angelo de Claro
Close
Sort by
Journal Articles

Complete remission with partial hematological recovery as a palliative endpoint for treatment of acute myeloid leukemia

Clinical Trials & Observations
Robert Q. Le, Donna Przepiorka, Haiyan Chen, Yuan Li Shen, E. Dianne Pulte, Kelly Norsworthy, Marc R. Theoret, R. Angelo De Claro
Journal: Blood
Blood (2024) 144 (2): 206–215.
https://doi.org/10.1182/blood.2023023313
Published: 2024
Includes: Supplemental data
Journal Articles

Response Rate, Event-Free Survival (EFS) and Overall Survival (OS) in Higher-Risk Myelodysplastic Syndromes (HR-MDS): U.S. Food and Drug Administration (FDA) Patient-Level Analyses

Nina Kim, Jonathon Vallejo, Jonathan Herz, Thomas Gwise, R. Angelo de Claro, Marc Theoret, Richard Pazdur, Kelly J. Norsworthy
Journal: Blood
Blood (2021) 138 (Supplement 1): 2604.
https://doi.org/10.1182/blood-2021-147558
Published: 2021
Journal Articles

Response Prediction to Isocitrate Dehydrogenase (IDH) Inhibitors in Patients with IDH1 - or IDH2 -Mutated Acute Myeloid Leukemia Using Clinical and Genomic Data

Emma C. Scott, Kamil Kural, Sean Smith, Michael Colgan, Alexander J. Ambinder, Gabriel Ghiaur, Nora Holmes, Dickran Kazandjian, Catherine Lai, Colleen McGuire, Lorraine Pelosof, Svetlana Petrovskaya, V. Ashutosh Rao, Amy Rosenberg, Luis Santana-Quintero, Joseph Wynne, Wenming Xiao, Yong Zhang, R. Angelo de Claro, Richard Pazdur, Julia A. Beaver, Kelly J. Norsworthy
Journal: Blood
Blood (2021) 138 (Supplement 1): 1285.
https://doi.org/10.1182/blood-2021-147099
Published: 2021
Journal Articles

FDA Oncology Center of Excellence Review of Real World Data Submissions Supporting Drug Development in Hematologic Malignancies

Donna R. Rivera, Jennifer J Lee, Melanie Royce, R. Angelo de Claro, Nicole J. Gormley, Paul G Kluetz
Journal: Blood
Blood (2021) 138 (Supplement 1): 5037.
https://doi.org/10.1182/blood-2021-153503
Published: 2021